Oncologist Dr. Ricardo Caponero clarifies doubts about the relationship between breastfeeding and breast cancer.
Breast cancer is a disease that can, in some cases, be prevented. This prevention, in general, consists of removing risk factors as early as possible.
Some cases of this neoplasm have a hereditary risk component. Today, we know about 21 genes related to breast cancer. In these cases, for eligible patients, prophylactic surgeries may reduce this risk. In addition, this group of women may be candidates for screening tests started when they are younger, with more specific exams and with shorter intervals.
However, most breast neoplasms do not have a hereditary character. For these, environmental factors may be the most relevant. Exposure to tobacco and its derivatives, excessive consumption of alcoholic beverages and various chemical substances are relevant, as is exposure to hormonal (estrogenic) stimuli.
All women produce estrogens, but some factors increase their action, such as hormone replacement therapy and the use of some types of contraceptive pills (those with low risk). Hormone replacement is not prohibited, but it should be done with caution, in properly selected patients, for the shortest possible time and, most importantly, with medical supervision.
Weight gain, especially after menopause, is also a risk factor. In addition to storing estrogens, fat has a higher concentration of an enzyme, called aromatase. The increase in fat mass composition also contributes to the generation of a systemic inflammatory state, which contributes to an increased risk of neoplasms in general and, in particular, for breast and endometrial cancer.
Diet (low in fat) and regular exercise are the two main modifiable factors for cancer prevention and should be started as early as possible (preferably in childhood).
The onset of periods at a younger age, the later menopause, no
having had children or having started procreation later and not breastfeeding also contribute
for a longer time of exposure to estrogen.
Pregnancy and breastfeeding also stimulate the maturation of breast cells to produce milk, and this is a factor for the good differentiation of breast tissue
We do not recommend any method to delay the first menstruation or to anticipate menopause
as a way to prevent cancer. In the same way that we cannot recommend that
women have many children, at the lowest possible age, for the same purpose. Essa
The measure causes very lasting social and economic impacts.
Breastfeeding is related to pregnancy, obviously. There are doubts regarding
At the optimal length of the breastfeeding period, most pediatricians recommend that she
occurs in the baby's first six months and may extend up to one year of age in
poorer populations, with fewer resources to provide an adequate alternative to
child feeding. Breastfeeding is a physiological act and has effects on the immunity of
newborn and in their physical and psychological development.
Although breastfeeding contributes to the reduction in the incidence of breast cancer,
its effect is very small when compared to other risk factors. We don't know your
impact on patients with hereditary mutations and their benefit is very small in
patients with other risk factors, such as obesity, sedentary lifestyle, smoking, etc.
A review of epidemiological data shows that the protective biological mechanism of breastfeeding remains unknown, although it is posited that it results from hormonal changes, such as estrogen reduction; removal of estrogens through breast fluid; excretion of carcinogens from breast tissue through breastfeeding; physical changes in mammary epithelial cells, reflecting maximum differentiation; and delayed reestablishment of ovulation.
Although breastfeeding is a potentially modifiable behavior, the practical implication of reducing the risk of breast cancer among premenopausal women with prolonged breastfeeding duration may be of marginal importance (less than 1% impact), particularly in Western societies.
Primary prevention of breast cancer is possible, but it depends on a set of measures so that it can be as effective as possible and, very importantly, it does not require adequate screening tests, which, although they do not reduce the incidence, are essential for simpler, less mutilating treatments and with greater chances of cure.
To conclude, breastfeeding is good, it should always be recommended, but its impact as a protective factor in breast cancer is very small.
Ricardo Caponero
— CRM 51,600/SP
Clinical Oncologist at the German Hospital Oswaldo Cruz
Oncologist Dr. Anelisa Coutinho explains a study presented at ASCO on the use of medication that
demonstrated 100% clinical response in a specific subgroup of patients with rectal cancer
When it comes to cancer, the greatest expectation is to have effective medications that can promote the cure of patients affected by this disease. Recently, the results of an important study dominated the national and international media in a surprising way.
This is a very small study that evaluated a medication called DOSTARLIMAB in patients with locally advanced rectal adenocarcinoma, stages II and III, with a genetic alteration
specifies: microsatellite instability or deficiency of DNA repair enzymes.
A microsatellites instability (MSI-H) it is an alteration found in less than 5% of patients with rectal cancer, i.e., approximately 95% of patients with this disease do not have this alteration. Based on data from studies on colorectal cancer and other tumors, it is known that patients with MSI-H are more susceptible to a form of treatment called immunotherapy, and DOSTARLIMAB It is a drug that belongs to this class of medications.
Treatment for locally advanced rectal cancer usually consists of radiation therapy, chemotherapy, and surgery. The idea of the authors of the work that was presented by Dr. Andrea Cercek at the largest American oncology congress, the ASCO congress, held in Chicago-USA this year, was to offer immunotherapy as initial treatment to patients with rectal cancer locally
advanced, assess the response after 6 months of treatment and only offer standard forms of treatment (radiotherapy, chemotherapy, followed or not by surgery) if there is no response to the experimental treatment.
The good surprise is that there was a complete clinical response, i.e. the absence of any evidence of residual tumor, in the first 14 patients evaluated.. The authors' expectation is to have a sample with at least 30 patients for this study, which is still ongoing. The number of patients is still small, the follow-up period after treatment is still short (median of 6.8 months), and
patients are still under observation. But without a doubt, this is already an excellent result, which can effectively modify the way of treating this special subgroup of patients with microsatellite instability, with a high response rate and saving them from side effects usually related to standard radiation therapy, chemotherapy and surgery.
Today, in oncological practice, microsatellite instability testing is already recommended for all patients with colorectal cancer, both for screening for a genetic syndrome called Lynch syndrome and to better guide treatment choices, as in the case of this study. The test is simple and widely available in many pathology laboratories, and is performed initially
in the tissue material from the tumor biopsy.
Science has evolved and we have learned to individualize treatments, identifying what best suits each patient and considering specific mutations that can be targeted by drugs aimed at these changes. The medical community and certainly the general population celebrated these results, which represent a lot and may favorably change the treatment perspective in this group of patients, but it should be noted that the still small number of
sample of the study, the prediction of a longer time for observing the results and the fact that it is applied to only a minority of patients with rectal cancer.
Anelisa K. Coutinho
Oncologist at AMO DASA
Member of SBOC, GTG, ASCO, ESMO
The Cura Project Institute engages with the Green July movement and provides information about these types of cancer
We're in #JulhoVerde, Head and Neck Cancer Awareness and Fight Month. The Cura Project Institute is also fighting to educate and demystify this type of disease.
Do you know where Head and Neck Cancer appears? These tumors affect the lips, tongue, floor of the mouth and roof of the mouth, sinuses, nasal cavity, tonsil, base of the tongue, pharynx, larynx, salivary glands, blood vessels, muscles and nerves in the region, and the thyroid gland.
But do you know the most common symptoms associated with these cancers that are often overlooked? Check it out!
They are highly preventable diseases!
It is important, in addition to the symptoms, to know the risk factors for diseases and to try to avoid them. They are:
- Avoid alcohol consumption
- Don't smoke
- Pray for oral hygiene
- Prevent HPV infection with vaccine and the use of condoms
Stay tuned!
One of the main problems for treating Head and Neck Cancers is the late diagnosis of diseases, which occurs in about 60% of cases, causing a significant loss of quality of life during and after treatment. But on the other hand, if diagnosed in the first stage, the chance of curing Head and Neck Cancer is greater than 80%.
Early diagnosis saves lives!
To learn more about the Cura Project projects, visit our Donation tab, follow our Social Networks @projetocura or contact us at eventos@projetocura.org
The researcher and nephrologist from the Cancer Institute, Dr. Verônica Torres, received the award at the Best of ASCO 2022 event.
On the same occasion of the Best of ASCO 2022 — Brazil Edition, the winner of the fourth edition of the Renata Thormann Procianoy Prize was announced. The winner was the researcher and nephrologist from ICESP — São Paulo State Cancer Institute, Dr. Verônica Torres Costa e Silva, principal investigator of a study on aspects related to renal treatment care in cancer patients.
Dr. Verônica Torres, who unfortunately cannot attend the event due to health reasons, was represented by the oncologist Prof. Dr. Gilberto Castro, physician and head of the head, neck and chest cancer group at ICESP Clinical Oncology and one of the co-authors of the study, who received the prize from the research patient Iramara Fluminhan and the President of the Cura Project Institute, Fernanda Schwyter.
About the research
The prospective study evaluates the performance of the 2021 CKD-EPI equation without racial coefficient in adults with solid tumors. Dr. Verônica Torres, lead author of the research, summarizes it as “the study on aspects related to renal treatment care in cancer patients” and is the best Brazilian poster presented during ASCO 2022. In addition to those already mentioned, the research also included the participation of Dr. Maria Del Pilar Estevez Diz and other researchers from ICESP.
The results of the study show that the coefficient associated with race must be removed from the equations to assess the estimated glomerular filtration rate, which represents an advance and must be incorporated into cancer treatment, the authors conclude.
For a better understanding of the research and with an explanatory approach for the general public, the Cura Project Institute, mediated by its President, Fernanda Schwyter, held a live on June 21 on Cura's Instagram profile (http://www.instagram.com/projetocura), with the participation of the award winner and lead author, Dr. Verônica Torres, together with co-author Dr. Gilberto Castro. The live show was also attended by Dr. Luis Fernando Correia, doctor and CURA ambassador. Check out the video recording hereto!
About the prize
Designed by the Cura Project Institute, the Renata Thormann Procianoy award was launched in 2019 and aims to make society aware of the benefits of research, valuing and encouraging medical researchers. In its previous editions, Dr. Thiago Bueno, Dr. Fernando Maluf and Dr. Luciana Landeiro were winners.
The story behind the creation of the award is about “a story of love and pain”, as the President of the Cura Project Institute, Fernanda Schwyter, always stresses when describing this significant trophy for the Institute. It pays homage to the story of the young Renata Thormann Procianoy, who dedicated two years of her life to helping her mother, Nora Thormann, find a diagnosis and treatment for a rare breast cancer. Thanks to this help, Nora was recruited for clinical research, was treated and recovered.
Unfortunately, Renata died some time later in an accident. Her mother then wanted to leave her daughter's name marked in the fight against cancer, through support for clinical research - the main reason for the existence of the Cura Project Institute, which fights daily to finance scientific studies and research in the treatment and cure of cancer.
To learn more about the Cura Project projects, visit our Donation tab, follow our Social Networks @projetocura or contact us at eventos@projetocura.org
The second edition of the Cura Meetings meeting will take place on June 10, during the Best of ASCO 2022, in São Paulo.
The new edition of the meeting CURE MEETINGS, organized by Cura Project Institute will deepen the discussions and debate on a topic that was highlighted at our last event, held at the Best of San Antonio Breast Cancer Symposium, which took place at the end of last April, the 29th. The proposal for the next Meetings will be to discuss “The public policy challenges aimed at regulating and encouraging cancer research in Brazil”.
Cura Meetings will take place in a hybrid way, on the day June 10, from 14:00 to 17:30, at the Pullman Ibirapuera Hotel, in São Paulo, on the occasion of the Best of ASCO 2022, an important event that will discuss the recent scientific advances that were presented at ASCO Annual Meeting 2022, the world's leading oncology event, which includes the LACOG and Ethics.
It is already known that research and innovation are fundamental requirements for reducing cancer incidence, but we also know that joint effort in the promotion of structural actions it is a globally recognized need. With the participation of renowned medical researchers, NGO leaders, patient reports and companies involved in encouraging cancer research, the Cura Meetings emerged from the need to expand the knowledge and engagement of different sectors of society to reduce the incidence of cancer in Brazil.
Click here and register for the event for free
Check out the CURA MEETINGS schedule below:
June 10 - 2 pm at 5:30pm
*ASCO News 2022 - Distance between scientific knowledge and what is offered to the population. Speaker: Dr. Carlos Barrios (oncologist);
*The importance of PRONON for funding research. Speaker: Dr. Paulo Hoff (oncologist);
*Legal status of clinical research in Brazil - PL 7082/2017. Speaker: Dr. Fábio Franke (oncologist);
*Presentations of successful cases funded by incentive programs. Speakers: Fábio Fedozzi from ABRALE and the CURA Project Institute
*Debate with NGO leaders, Politicians and Public Officials
*Launch of a mobilization campaign
*Closing
The 2nd edition of the event created by the Cura Project Institute concluded with a social mobilization mission
On June 10th, the Cura Project Institute held another edition of Cura Meetings, an event that aims to bring together medical researchers, representatives of NGOs and civil society, in discussions in favor of clinical oncology research in Brazil.
In an intense afternoon filled with many positive and constructive discussions, Cura Project Institute, with the support of LACOG (Latin American Cooperative Oncology Group), Ethics and Daiichi-Sankyo Brazil, Took up the topic “The challenges of public policies aimed at regulating and encouraging cancer research in Brazil” to an essential framework for the fight against cancer in our country.
O Cura Meetings, which in this edition took place on the occasion of Best Of ASCO 2022 Annual Meeting, in São Paulo, in person and online, put common interests and the importance of joint efforts in social mobilization to reactivate the program PRONON — National Oncology Care Support Program, an important government grant that allows companies taxed for “real profit” to allocate up to 1% of their Income Tax to fund Research and whose regulations expired at the end of 2021. The Cura Project Institute is now fighting to reactivate the program, which benefits clinical research, such as NEOSAMBA, approved by the program last year.
In the latest edition of Meetings, The participation of the National Cooperation Project Coordinator of Ministry of Health, Marcela Iwano. In addition to it, we also highlight the participation of Dr. Paul Hoff, president of the Brazilian Oncology Society (SBOC), who spoke about the importance of PRONON to promote clinical research, since he participated in the creation of the program, which was established by Law No. 12,715/2012.
In the debate on the topic, moderated by Dr. Rafael Laurindo and Dr. Ricardo Caponero, It also included the participation of Dr. Fábio Franke, director of the Clinical Research Alliance, as well as the always essential presence of Dr. Carlos Barrios. The oncologist and founder of LACOG brought to the meeting the news of Annual Congress of the American Society of Clinical Oncology — ASCO 2022. In addition to them, the executive director of ABRALE, Fábio Fedozzi, addressed the success stories financed through incentive programs, and the Senator Mara Gabrilli, who attended the video meeting, in which he emphasized the importance of the permanence of PRONON and the support for Cura Project Institute.
The event was attended in person by representatives of ABRACRO, Oncogia, ABRALE, scientific committee of Cura Project Institute And the research patient Iramara Fluminhan, in addition to several other institutions and patients that participated through the live broadcast on YouTube.
O Cura Project Institute Also thanks to all the participants in the second edition of Cura Meetings, with an important mission ahead with the launch of social mobilization for the reactivation of the program PRONON and in favor of public policies aimed at regulating and encouraging oncological research in Brazil.
To learn more about the Cura Project projects, visit our Donation tab, follow our Social Networks @projetocura or contact us at eventos@projetocura.org
Created by the Cura Project Institute, the meeting brought together renowned doctors, NGOs and companies to discuss scientific research.
The first edition of the Cure Meetings! Created by the Cura Project Institute, with support from LACOG (Latin American Cooperative Oncology Group), the meeting was part of the program Brazilian Breast Cancer Conference, at the Best of San Antonio Breast Cancer Symposium, and promoted several discussions among renowned doctors in the area on various topics, and provided an opportunity for the public to learn about the benefits and challenges for carrying out research in the fight against cancer.
In this edition, we have 3 different meetings: the Cure Meetings Donors, with the institutions involved in carrying out and developing Neosamba Research; Cura Medical Meetings, who addressed the topic “Innovation in research funding and patient recruitment”; and Cura Meetings NGOs, aimed at leaders of health NGOs and Patient Associations.
O Cura Meetings NGOs It included lectures by renowned doctors and a discussion about “Clinical Research and Social Inclusion”. At the time, we were attended by the following institutions: Abrale, Oncoguia Institute, Red Alianza Latina, Institute Side by Side by Side for Life, Women's Network to Fight Cancer, Oncology Observatory and Overcoming Cancer Institute, TJCC Movement, as well as several others that participated online. In addition, we rely on remote testimonials from research patients Iramara Fluminhan and Ilma Lopes, essential for understanding the practical reality of those who participate in scientific studies. On the occasion, we also highlight the distinguished presence of the doctors Dr. Ricardo Caponero, Dr. Laís Souza, Dr. Eduardo Zucca, Dr. Ruffo Freitas Junior, Dr. Luciana Landeiro and Dr. José Márcio Figueiredo.
The success of the event was only possible due to the participation of everyone who was with us online and in person! We thank everyone and especially LACOG and our speakers!
On June 10, we will have a new edition of Cura Meetings! Soon, we will bring you new information. Wait!
To learn more about the Cura Project projects, visit our Donation tab, follow our Social Networks @projetocura or contact us at eventos@projetocura.org
With the objective of expanding the knowledge and engagement of different sectors of society to reduce the incidence of cancer in Brazil, the Cura Project Institute will hold a series of meetings called “Cura Meetings” in 2022, which will promote meetings and discussion among renowned doctors in the area, on various topics and giving the public the opportunity to learn about the benefits and challenges for carrying out research in the fight against cancer.
The premiere of Cura Meetings will take place on April 29, during the Best of San Antonio Breast Cancer Symposium, organized by GBECAM — LACOG, at the Intercontinental Hotel in São Paulo.
For this event, three meetings are reserved: Care for Meetings Donors, where the institutions involved in carrying out and developing Neosamba Research, sponsored by incentive law, will be presented with its benefits for society and for donor companies. The meeting Cura Meetings NGOs, with an approach to the topic “Clinical Research and Social Inclusion” with the participation of NGO leaders and renowned medical researchers and the third meeting, the Cura Medical Meetings, where it will be discussed about “Innovation in research funding and patient recruitment”, focused on the medical field.
The Cura Project Institute is a non-profit institution, based in Brazil and unique in Latin America, whose objective is to finance academic research in the area of oncology.
According to the World Health Organization, as early as the next decade, two out of every three people will be diagnosed with cancer, which is expected to become a true epidemic. The consolidation of research activity is one of the solutions to meet the needs of the population, particularly those that depend on the public health system, reducing discrepancies and facilitating access to the best treatments.
To learn more about the Cura Project projects, visit the projectocura.org website, follow our Social Networks @projetocura or contact us at eventos@projetocura.org
The Ministry of Health published, on November 18, in the Federal Official Gazette, the approval of the public notice registered in 2019 by the Cura Project Institute, which benefits the NeoSamba Study in the PRONON - National Oncological Care Support Program. Thus, Pronon opens doors for the Cura Project Institute to have more and more hope in its mission to support oncological research.
According to the Federal Government website, “Pronon's purpose is to encourage actions and services developed by non-profit entities, associations and private foundations that work in the field of oncology. The purpose is to expand the offer of services and expand the provision of medical care; to support the formation, training, and improvement of human resources at all levels; and to carry out clinical, epidemiological, and experimental research.”
The National Oncology Care Support Program was established by Law 12,715/12, which allows companies taxed for “real profit” to allocate up to 1% of their Income Tax to finance research such as the NeoSamba Study, which seeks to raise funds to fund the processing of data for a 100% Brazilian study, which studies a new sequencing of the treatment of HER2-negative breast cancer.
The NeoSamba study is a randomized clinical trial, which is in phase 3, studying a new treatment sequence with neoadjuvant chemotherapy (before breast surgery) and will include the treatment of nearly 500 women over three years.
The approval of the NeoSamba Study in Pronon, which is valid for the 2021 fiscal year, does not guarantee the transfer of funds, and the raising of companies to join the program is the responsibility of the Instituto Cura Project and partner groups.
The link provides access to the Public Notice in its certified version: https://pesquisa.in.gov.br/imprensa/jsp/visualiza/index.jsp?data=18/11/2021&jornal=515&pagina=163
ORDINANCE NO. 538, DATED NOVEMBER 16, 2021
DOU - section I published on 11/18/2021
Companies that are interested in supporting the NeoSamba Campaign can contact the Cura Project Institute through its President Fernanda Schwyter 011.9.3080.0811 or via email: campanhas@projetocura.org
Promoted by the Cura Project Institute, Patient Forum “Inside Cancer — EMama edition”, held on October 6, provided a transformative moment for cancer patients, NGO leaders, and other interested parties. The focus of the event was the update on breast cancer and its treatments and the presentation of the latest research with the biggest names in oncology and clinical research in the country.
The Forum, 100% online and free, received an excellent public reception: more than 300 registered! There were more than 3 hours of programming, with 6 conferences, 1 question session, a major research debate and the participation of 13 professionals in the field.
We had the participation of the specialists:
The Forum was sponsored by Roche, the support of the Cristália Laboratory and LACOG, in addition to the support of the following institutions:
The event also marked the official launch of the “Together we can be stronger than cancer” campaign to raise financial resources to enable phase 3 of the NeoSamba Study to be carried out.
Many thanks to everyone involved: speakers, medical coordinators, moderators, and the Cura team!
Click here to learn more about the Campaign “Together we can be stronger than cancer” and participate!
Brazilian researchers are seeking resources for a study that is close to confirming the best preoperative treatment sequence for breast cancer, benefiting women around the world.
The Cura Project Institute launched the crowdfunding campaign “Together we can be stronger than Cancer” that seeks to raise funds to fund one year of data processing for the Neosamba study, a 100% Brazilian study, which studies a new treatment sequence for HER2-negative breast cancer, with neoadjuvant chemotherapy (before breast surgery) and will include the treatment of almost 500 women over three years.
https://www.youtube.com/watch?v=Sji8EVV7q_4&t=9s
The Neosamba survey is moving towards phase 3, when the number of people investigated for a longer period of time is expanded. However, resources are lacking to begin this process, which Dr. José Bines, oncologist and principal investigator of the study, defines as a “confirmatory scientific study”.
“This is a 100% Brazilian survey and 100% conducted in reference institutions that serve SUS patients. There is no relationship with the pharmaceutical industry. All stages of designing and conducting the study are carried out by the researchers themselves, and now with the Cura Project Institute, which has helped us to raise funds for the completion of phase III”, explains Dr. José Bines.
With the proof of the results in phase 3, in addition to the expansion of access to new therapies, an improvement in the quality of life and the increase in the chance of a cure for patients, an extraordinary benefit will be their immediate application, since the medications are now available in the Brazilian public network, without any additional cost increase.
The Neosamba Phase 3 crowdfunding campaign is an initiative of the Cura Project Institute, in partnership with LACOG (Latin American Cooperative Oncology Group), GBECAM (Brazilian Breast Cancer Studies Group). Actress Patrícia Pillar joined the team as an ambassador for the campaign, acting on a voluntary basis as spokesperson for the cause in the promotional materials. Oncology and mastology doctors are also participating as godmothers and godparents in the campaign.
Learn more and make your donation
To learn more details and support the campaign, interested parties can access the Benfeitoria platform by clicking here. Donations can be made by credit card, bank slip or PIX
It is also possible to make a direct donation to the Cura Project Institute through:
If you would like to make a donation in another way, or as a company (PJ), please contact us by e-mail: campanhas@projetocura.org
Make your donation, share, tell your friends and family! Together we can be stronger than cancer!
Changing that story is up to you!
Cura Project Institute brings together specialists to talk with patients and NGOs
The Patient Forum “Inside Cancer” - Breast Edition will take place on October 6th. Aimed at patients, family members, and patient association leaders and NGOs, the event will be an opportunity for the public to ask questions about breast cancer. In addition, debates and classes will take place on advances in treatments and the latest in clinical research, with specialists in the fields.
Check below who the professionals are and the topics that will be on the program!
Breast Cancer
· Early Diagnosis X Impact of the Covid 19 Pandemic — Dr. Heloisa Resende
· Metastatic Breast Cancer: epidemiology and unmet needs — Dr. Sérgio Simon
· New Treatments: the era of ADCs? — Dr. Max Mano
· Fertility and Breast Cancer — Dr. Ricardo Caponero
· Questions Session, moderated by the bloggers from “Papo de Câncer”, Paula Dultra and Carolina Magalhães, with doctors.
Clinical Research in Brazil
· LACOG Study Scenario — Dr. Gustavo Werutsky
· Amazona Study — Dr. Daniela Rosa
· DEBATE: What is the importance of socio-demographic data to guide public policy actions in health? Patients' Rights/Research Funding/Benefits of research conducted in Brazil? Dr. Carlos Barrios; Dr. Daniela Rosa; Dr. José Bines; Dr. Maira Caleffi — FEMAMA; Luciana Holtz — Oncoguia; and Fernanda Schwyter — Care.
The event, of national scope, is organized by the Cura Project Institute and will be 100% online and free. Don't miss this opportunity! Sign up now!
“Inside Cancer” Patient Forum — MAMA Edition.
Online event with free registrations
October 06, 2021, from 15:00 to 18:30
Registrations via the link: http://www.forumcura.com.br
Text by Renata Ettinger and Paula Dultra
Check out the Cura Project Institute donation page and find out how to help! It's just click here!
CLICK HERE and sign up now for the “Inside Cancer” Patient Forum - Breast edition.
NGO will bring together renowned doctors to answer cancer patients' main questions about breast cancer and clinical research at a free online event.
On October 6th, the Cura Project Institute will hold the Patient Forum “Inside Cancer” — Breast Edition. The event, of national scope, will be 100% online and free and will include the participation of renowned speakers and NGOs of great relevance in the country.
Focusing on patients, both from the Unified Health System - SUS, and from the private system, family members and patient association leaders, the Forum aims to educate and inform about the disease and its treatments and to present the latest research in Brazil.
We will discuss the reality of the disease in the country, its challenges and solutions, so that all patients receive appropriate treatment. Topics such as fertility, new treatments, metastatic breast cancer and research benefits will be addressed, with the eyes of leading experts in the field. Patients will also have the opportunity to ask questions with the specialists present. To check out the full schedule, click here.
About the Cura Project Institute
The Cura Project Institute is a non-profit institution and is the only one in Latin America that seeks to make the population aware of the benefits of research in the fight against cancer, in order to create a culture of philanthropy to finance them.
In its wide network of collaborators, Cura has researchers, oncologists, radiologists, surgeons and other health professionals who carry out various types of research. In addition, it also has the support of companies from various sectors, hospitals, research centers, NGOs, public institutions, volunteers and patients, all partners in the fight against cancer.
About the disease
Every year, more than 620,000 new cases of cancer are registered in Brazil (INCA, 2020). When it comes to breast cancer, the disease accounts for almost 30% of new cancer cases in Brazilian women (INCA, 2020) and is responsible for 16% of cancer deaths in women (INCA, 2019). Thus, it is necessary to encourage new public policies and technologies to promote the improvement of the outcomes of these patients.
Service:
“Inside Cancer” Patient Forum — MAMA Edition.
Online event with free registrations
October 06, 2021, from 15:00 to 18:30
Registrations via the link: http://www.forumcura.com.br
Text by Renata Ettinger and Paula Dultra
Check out the Cura Project Institute donation page and find out how to help! It's just click here!
CLICK HERE and sign up now for the “Inside Cancer” Patient Forum - Breast edition.
Vaginal dryness is one of the common side effects among cancer patients during or after treatment. This symptom is associated with the onset of menopausal genitourinary syndrome related to the treatment of breast cancer (surgery, hormone therapy, radiation therapy, or chemotherapy).
Among the patients treated for this type of cancer, it is estimated that around 50 to 60% will develop this syndrome whose symptoms include, in addition to vaginal dryness, burning when urinating, pain in the lower abdomen, recurrent urinary tract infection, loss of urine, pain during sexual intercourse or for tests, bleeding, itching, a loose vaginal feeling.
The treatments available so far have some limitations, such as a short-term effect, the risk of absorption into the blood (in the case of using hormones) and stimulation of tumor cells, and the high cost.
This study, genuinely Brazilian and Soteropolitan, coordinated by Dr. Daniela Barros, an oncologist and specialist in female cancers, and by Dr. Patrícia Lordêlo, a physiotherapist and specialist in gynecology, seeks to improve the quality of life of patients who have had breast cancer, through the combination of pelvic physiotherapy and the use of vaginal LEDs.
The protocol includes carrying out five sessions of pelvic physiotherapy associated with the blue Light Emitting Diode (LED), due to its healing potential, with an interval of seven days between them, the monitoring of symptoms through detailed questionnaires and the collection of a 'simplified preventative'.
The research is carried out at the Pelvic Floor Care Center, which operates at the Patrícia Lordêlo Institute in Salvador-Bahia, focusing on patients who have been treated for breast cancer and are cured, up to 65 years of age.
To find out more, check out the live broadcast on Instagram from the Cura Project Institute with the coordinators of this research.
Text by Renata Ettinger
Check out the Cura Project Institute donation page and find out how to help! It's just click here!
From ancient civilizations, through the famous Prohibition Law in the United States and reaching today's permissiveness, the consumption of alcohol is so popular that we even forget that its substance is a drug like any other, the difference is that it is legalized. Being a drug, its ingestion can cause serious consequences. To shed light on such ills ten scientists came together to investigate the consequences of drinking alcohol and discovered that 4% of all new cancer cases in 2020 were attributed to alcohol. The study was published this month in the British scientific journal The Lancet Oncology.
Entitled from”Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study” the research carried out highlights that alcohol consumption is associated with a wide range of diseases, including cancers of the upper aerodigestive tract (oral cavity, pharynx, larynx and esophagus), colon, rectum, liver and breast. These contributed to 6.3 million cases and 3.3 million deaths globally in 2020.
It is estimated that 741,300 (4%) of all cancer cases registered globally were caused by the consumption of alcoholic beverages. Of those, 568,700 were in men and 172,600 in women. This fact follows the trend that men traditionally drink more than women. The study also points out that most cases are due to excessive alcohol consumption (346,400 of the cases) and risky consumption (291 800 of the cases), while moderate alcohol consumption contributed to 103 100 of the records and drinking up to 10 g a day caused 41,300 cancers.
Even though it is related to cancers in various parts of the body, researchers highlight that the most common cases of cancer associated with alcohol are those that appear in tissues that come into direct contact with the substance. A publication of the magazine in 2017 I already drew attention to the fact that “a three-fold increase in the recommended alcohol limit increases the risk of esophageal cancer by eight times, leading to estimates that three-quarters of esophageal cancers are due to high alcohol consumption. Because esophageal cancer has a 5-year survival rate of less than 10%, prevention is paramount.”
If we take into account that the research was carried out in the midst of the COVID-19 pandemic, which still causes emotional stress and deprives people of various social activities around the world, the situation becomes more alarming. The Pan American Health Organization (PAHO) conducted research in 2020 that proves the intensification of alcohol abuse by 93.9% during social isolation. Of this amount, 52.8% had anxiety, nervousness, insomnia, worry, fear, irritability, and difficulty relaxing. It is understood that the beverage was used to alleviate everyday stress. Thus, the scale of the danger posed by alcohol is worrying, since around 2 billion people already consume alcoholic beverages regularly in times of stability.
The whole scenario sounds alarming, after all, there are studies that state that there are benefits of using alcohol moderately, such as a glass of wine a day, for example. However, the British journal study casts doubt on these statements and comments that “historical statements about the benefit of alcohol are probably misinterpreted or exaggerated, because a lower threshold for cancer risk related to alcohol consumption has not yet been identified”.
There are also associations between alcohol and many other types of cancer, but researchers argue that the precise role of alcohol in these cases requires that new research be fully dissociated from ecological and lifestyle factors. This, therefore, our body is affected by our environment, such as pollution and the quality of the water we drink, and by how hard we work and sleep; what we eat; how normal it is to drink in our culture and even what alcoholic beverage is most consumed in the place where we live. The challenge is to separate what is the effect of alcohol alone and what is the effect of alcohol added to other factors.
Thus, we observed that science continues the movement that involves contradictions and a lot of collective work until it reaches points of communion. The study presented is another piece developed by science to assemble the puzzles that are cancer studies.
Even aware that alcoholic beverages are an intrinsic part of the culture of several nations and that the abolition of their consumption may not take place, the authors of the study”Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study” believe that due to the risk of cancer and other diseases, reeducation actions are needed to preach a safer and more moderate consumption of alcoholic beverages, in addition to stricter regulation for their consumption, even if this causes strong political and commercial opposition.
Authors: Harriet Rumgay, BSc; Kevin Shield, PhD; Hadrien Charvat, PhD; Pietro Ferrari, PhD; Bundit Sornpaisarn, PhD; Prof. Isidore Obot, PhD; Farhad Islami, PhD; Prof Valery E P Lemmens, PhD; Prof. Jürgen Rehm PhD; and Isabelle Soerjomataram, PhD.
Text by Letícia Barbosa
Hospital-acquired infections (also called Health Care-Related Infection - IRAs) are complications that can be caused by microorganisms, such as bacteria and viruses. Some of the microorganisms that cause hospital infections are found in the environment and some are part of our body.
Although they generate a lot of fear and have serious variants, infections can be prevented with simple preventive measures. Shall we understand more about the subject?
The most common types of hospital infections include those associated with a surgical wound or the insertion of medical devices, such as an intravenous drip, urinary catheter, or wound drain. Such a misfortune can occur because many sick people have their immune systems compromised, making them more susceptible to contracting an infection. In Brazil, the most common are respiratory infections, with pneumonia being the most common; urinary tract infection; skin infections, and blood infections.
In addition, there is also the risk of contamination by superbugs, which arise when antibiotics are administered improperly, which can cause a natural selection of the most resistant bacteria. In the Brazilian context, the incidence of superbugs is striking Acinetobacter spp, Klebsiella pneumoniae, Pseudomonas aeruginosa and E.coli.
In order for the hospital body to avoid the incidence of these infections, there are a series of safety protocols to be followed for prevention. The most common are: washing hands with soap or using alcohol-based gel; using protective equipment, such as gloves, lab coats, masks, and eye protectors; separating infectious patients from others; disinfecting medical equipment between the use of one patient and another; in addition to maintaining a clean environment.
Despite these efforts, some patients are still at greater risk than others of contracting an infection while hospitalized. This can happen especially with people who have illnesses that affect their body's ability to fight infections such as cancer. However, the elderly, newborns; people with impaired immunity (AIDS patients or post-transplant patients, for example); diabetics; people with vascular diseases and patients who use invasive devices, such as urinary catheter insertion, venous catheter insertion and the use of ventilation by devices are also vulnerable to hospital infections.
To reinforce the safety of all patients, we, visitors, family members and friends of sick people can also do our part to prevent the onset of hospital infections. Always wash your hands after using the bathroom or before eating; do not visit if you have symptoms of any illness; avoid touching a wound or device inserted in the patient's body; inform the health professional who cares if the area surrounding any of the lines or tubes inserted in the patient's body becomes red, swollen, or painful; avoid talking too close to the patient to prevent infection by respiratory diseases and do not be afraid to ask a health professional if he cleaned his hands before doing any procedure.
The actions described above seem simple, but they have the power to make all the difference in the safe evolution of a medical treatment. Therefore, remaining vigilant about the environment and your own habits is the first step so that we can keep the hospital environment safe for patients, staff, and the people we love. Be aware, follow hygiene protocols and health professionals' guidelines!
Text by Letícia Barbosa
This Wednesday (16), the public was able to learn about the research that won the Renata Thormann Procianoy award, designed by the Cura Project Institute. The research, entitled “Randomized study using electric hand warmer versus observation to reduce discomfort during scalp cooling for prevention of chemotherapy-induced alopecia”, is led by Dr. Luciana Landeiro and studies ways to provide general and thermal comfort for breast cancer patients who use scalp cooling during their chemotherapy treatment as a way to prevent Alopecia Areata (hair loss). The award ceremony took place on the 16th and was part of the program of the Best of ASCO 2021 Annual Meeting — Brazil Edition.
Winner's profile
A Northeastern woman, Dr. Luciana Landeiro has breast cancer and gynecological tumors as her main line of research. The doctor began her career as a scholarship holder in a hepatology research group at the Federal University of Bahia. Years later, in his oncology residency, he focused his efforts on improving the quality of life of cancer patients.
In addition, she completed postgraduate studies in clinical research from Harvard Medical School. Luciana then became a PhD in Clinical Oncology from the University of São Paulo and chose the Survivorship line of research, in which she evaluated return to work rates in patients with breast cancer.
Dr. Luciana Landeiro is a member of the Brazilian Society of Clinical Oncology (SBOC); of the American Society of Clinical Oncology (ASCO) and coordinator of the Research Center of the Oncology Center of Bahia (NOB)/Oncoclinics Group.
About the research
The study was developed within the area of quality of care for patients with breast cancer and was conceived jointly by Dr. Luciana Landeiro and Dr. Clarissa Mathias. The study population were patients diagnosed with early, locally advanced breast cancer.
Research volunteers underwent scalp cooling during chemotherapy treatment as a way to prevent the adverse effect of Alopecia, which is hair loss. In the study, patients were randomized, in a ratio of 1 to 1, for intervention with the use of electric hand warmers versus observation during scalp cooling. The main objective was to assess the participants' overall comfort by evaluating comfort and thermal sensation.
The results of this pilot study suggest that the use of hand warmers has a favorable and consistent impact on overall and thermal comfort among breast cancer patients who use scalp cooling during their chemotherapy treatment. These results are an initial indication that a simple device can improve patients' quality of life and perhaps reduce interruptions in treatment with the thermal cap.
History of the Renata Thormann Procianoy Prize
The award was launched by the Cura Project Institute in 2019 during the Best of ASCO and pays homage to the story of Renata Thormann Procianoy who dedicated two years of her life helping her mother, Nora Thormann, to find a correct diagnosis and treatment for breast cancer. Nora recovered when she was recruited for research coordinated by doctor Dr. Roberto Miranda at the MD Anderson hospital at the University of Texas, USA.
The Cura Project Institute is especially grateful to Cristália for encouraging research through support for the 3rd edition of the Renata Thormann Procianoy award.
Text by Letícia Barbosa
With information from: Best of ASCO 2021 Annual Meeting - Brazil Edition
The ASCO 2021 Annual Meeting is the largest oncology conference in the world and the most awaited by those who work in this area, since every year it presents several studies that change clinical practice. In 2021, due to the pandemic, for the second consecutive year the event was held 100% online. Each year there are countless studies that can transform our practice or appear as an option for change.
Below are some highlights from ASCO 2021:
Mamma: adjuvant study with PARP inhibitors in patients with BRCA1 and BRCA2 mutations. There was a significant increase in disease-free survival with the use of olaparib. We await the overall survival data.
Prostate: treatment that demonstrated an increase in overall survival with LU-PSMA 617 therapy in PSMA positive castration-resistant prostate cancer undergoing previous treatments with new-generation antiandrogens and taxanes. This study already changes clinical practice because it has demonstrated an increase in overall survival.
Head and neck: use of immunotherapy combined with standard chemotherapy for first-line recurrent/metastatic nasopharyngeal carcinoma. There was a significant increase in progression-free survival. It is worth waiting for data on overall survival and quality of life.
Rim: immunotherapy in the adjunctive treatment of clear cell renal cancer. It shows an increase in disease-free survival, but it is still immature for the analysis of overall survival, but with a tendency to be positive.
These are just a few examples of several studies presented that may give new directions to our clinical practice or, if they do not change it yet, open up new possibilities in the treatment of various types of neoplasms.
For this reason, we always stress the importance of clinical research. It really saves lives! And there's nothing like a congress of this size to encourage us more and more to Do research.
Several Brazilian centers and researchers from our country participated in these and other studies presented at ASCO, which fills us with pride and encouragement to continue the fight for facilitate research practice in our country. The patients gain the most from this.
June 10, 2021 - Due to the COVID-19 pandemic, we observed how necessary it is to celebrate research efforts and share knowledge. In view of this, for the first year, the pharmaceutical company Cristália will support the Renata Thormann Procianoy award. The award will take place on June 16, from 8 pm to 8:30pm, during the Best of ASCO 2021 Annual Meeting Congress - Brazil Edition. This, which is one of the largest oncology events in the country, can be viewed virtually from June 14 to 16. The conference is free, aimed at doctors and health professionals, and is open for registration. Those interested can register by clicking hereto.
Cristália, our new partner, is a Brazilian pharmaceutical, pharmachemical, biotechnological and research industrial complex that has been leading the innovation market for 47 years and has been considered the best pharmaceutical company in Brazil for 3 consecutive years. With regard to cancer patients, Cristalia is also a pioneer and inaugurated in 2019 the Pharmoquimica plant for oncological products, which is already producing several high-potency drugs (IFAs) for oncology in Brazil. Are you curious and want to know a little more about Cristália? Access your portfolio hereto!
More than providing due recognition, the Cura Project Institute seeks, with the Renata Thormann Procianoy award, to motivate the scientific community to continue with its excellent research and to renew its impetus to help others and future generations, since working in research in Brazil can be challenging and exhausting due to the lack of incentives. In addition, the intention is to disseminate among scientific peers and the lay public what has been innovative in our science in search of quality of life for cancer patients and more effective treatments against cancer.
The award was launched by the Cura Project Institute in 2019 during the Best of ASCO, whose winner was Dr. Thiago Bueno. The award pays homage to the story of Renata Thormann Procianoy who dedicated two years of her life to helping her mother, Nora Thormann, find a correct diagnosis and treatment for breast cancer. Nora recovered when she was recruited for research coordinated by doctor Dr. Roberto Miranda at the MD Anderson hospital at the University of Texas, USA.
This year the Best of ASCO 2021 will have lectures on the topics: Genitourinary; Skin Cancer and Sarcomas; Head and Neck/Neuro; Breast; Gynecology; Hematology; Gastrointestinal and Lung. The speakers are among the most renowned and innovative researchers in the country, so we invite everyone to participate in this moment of knowledge exchange and communion, join us!
Text by Letícia Barbosa
With information from: Cristália and Best of ASCO 2021 Annual Meeting - Brazil Edition
As part of its mission to democratize access to information about science, the Cura Project Institute follows the tradition of promoting informative lives on Instagram, always with renowned guests from the fields of medicine and research. On Thursday (27), the debate was about the status of clinical research in the midst of a health crisis. The guests were the oncologists and researchers Dr. Heloisa Resende and Dr. Fábio Franke. The mediation was carried out by Fernanda Schwyter, president of the Cura Project Institute.
On live, it was discussed how the pandemic made it difficult to continue the treatment of oncological patients because of the risk of the disease. In addition, Dr. Resende and Dr. Franke state that the fear of going to hospitals, in addition to the lack of vacancies in the Unified Health System (SUS), has led to underreporting of new cases of cancer. “Faced with the pandemic, people are not having the opportunity to receive a diagnosis. This situation gives a poor prognosis for the coming years, because early treatment is essential against cancer. Thus, there will be an increase in the number of patients needing emergency treatment for the disease and the SUS will find it difficult to witness this accumulation of people that will come”, lamented Dr. Heloisa Resende.
The solution to “relieve” the SUS would be to invest and reduce bureaucratization of access to clinical research who study treatments and cures for the most diverse cancers. However, just as the arrival of COVID-19 accelerated scientific collaboration processes and popularized the importance of research for the lay population, a certain mistrust has emerged about clinical tests and research. According to Dr. Fábio Franke and Dr. Heloisa Resende, there was a loss of reference. “The research fell on the lips of the people, which was positive, but what research should the population believe in? There's so much denial and Fake News. The challenge is: how to filter information as a layman?” , asked Dr. Heloisa Resende. For Dr. Franke, “education must be brought closer to health, so that information can be shared about vaccines, good health habits, and self-care.”
At the end of the live, there was talk of the need to publicize the rights and duties of the research patient, in order to demystify the belief that such participants are guinea pigs. Dr. Fábio Franke also defended the urgent need to regulate and reduce bureaucratization of clinical studies in Brazil, because the context of the pandemic showed us how much more agile processes are fundamental for us to save lives and have access to modern treatments. The oncologist is one of the supporters of Bill 7082/2017, authored by Senator Ana Amélia, which seeks to regulate and expedite the conduct of clinical research with human beings by public or private institutions in Brazil, thus creating principles, guidelines, and rules for conducting such studies.
Not only in the context of the health crisis, but also in the treatment of cancer, the regulation of clinical studies has the power to open Brazil up to the latest in international medicine. Dr. Franke reports that “there is a great need for new treatments on the part of cancer patients that is not being met because few studies from other countries are able to effectively reach Brazil. This is because of the bureaucracy and the lack of predictability. [...] I have already worked on the regulatory side and we spent a year organizing only the documentation. In the end, the studies did not open in Brazil or were canceled because recruitment in the rest of the world was simply closed”.
In the live interview, the doctor also explained that the research is extremely organized, so foreign studies are afraid of investing in a country where slow processes make it difficult to know the answers of ethical and health advice; how many patients can participate in the study and when the work can actually begin. Then, the studies, which are mostly global, choose the countries with the most available scenarios.
Dr. Fábio Franke and Dr. Heloisa Resende closed the live with the message that doctors and researchers must have the right to provide new studies and treatments for patients and there is a great demand for such alternatives and interested in applying as research volunteers.
To watch this and other lives follow our Instagram @projetocura.
Text by Letícia Barbosa
According to the World Health Organization, tobacco use causes 8 million deaths every year. To make the population aware of the risks of smoking, May 31 is marked as World No Tobacco Day. The date, already charged with importance, becomes even more essential, as recent evidence shows that smokers are more likely to develop severe cases of COVID-19 and to die.
On April 29, 2020, a review of studies by public health experts convened by the WHO found that smokers are more likely to develop more severe versions of the coronavirus, compared to non-smokers. This is because COVID-19 is an infectious disease that mainly attacks the lungs and smoking is a risk factor for many respiratory infections, because it damages the lungs, which increases the severity of respiratory diseases. That is, smoking decreases lung function, making it harder for the body to fight against coronavirus and other diseases.
According to information from the National Cancer Institute (INCA), tobacco is also related to approximately 50 diseases, including various types of cancer (lung, larynx, pharynx, esophagus, stomach, pancreas, liver, kidney, bladder, cervix, leukemia), respiratory system diseases (pulmonary emphysema, chronic bronchitis, asthma, respiratory infections) and cardiovascular diseases (angina, acute myocardial infarction, high blood pressure, aneurysms, stroke, thrombosis). These diseases are the comorbidities we hear so much about on the news, which put people at greater risk if they are affected by coronavirus.
Faced with this situation, it is essential to seek ways to overcome cigarettes, not only because they leave those who use them more vulnerable to COVID-19, but because their use alone causes various health problems. The challenge is tough, but the Unified Health System (SUS) offers free treatment for those who wish to quit smoking. The initiative is carried out through the National Tobacco Control Program (PNCT). The program is provided by the Ministry of Health in partnership with INCA and covers all Brazilian states and the Federal District. Click here and learn where you can find anti-smoking treatment near you.
With information from: World Health Organization and Cancer Institute Brazil
In youth we feel immune, we are discovering the world, who we are and we have our whole lives ahead of us. It is common that during this period of life the concern for health is something distant, an issue for older people. Unfortunately, cancer is a disease that affects everyone, including the youngest, who feel so invincible at that age.
According to the oncologist Dr. Eduardo Romero, “people used to believe that cancer was a disease of older people, since it was more common in old age. Today, unfortunately, that has changed dramatically. We increasingly see young people with cancer, largely due to lifestyle changes such as: inadequate diet, overweight/obesity, sedentary lifestyle and stress”.
Oncoguia points out that among the most common cancers in teens, aged between 15 and 19 years, are: Lymphomas, Leukemias, Thyroid Cancer, Brain and Spinal Cord Tumors, Testicular Cancer, Bone Tumors and Soft Tissue Sarcomas, Melanoma, and Ovarian Cancer.
Already among the young adults, aged between 20 and 39, are: Brain and Spinal Cord Tumors, Colorectal Cancer, Testicular Cancer, Thyroid Cancer, Female Genital Tract Cancers, Bone Tumors and Soft Tissue Sarcomas, Melanoma, Lymphomas, and Breast Cancer.
We can observe this alarming picture when analyzing North American and Brazilian studies conducted in recent years. The first study in question, carried out by the University of Pennsylvania School of Medicine, collected data from nearly half a million patients between 15 and 39 years of age with cancer, between 1973 and 2015, and discovered that cancer cases among young people increased 30% in the last four decades, making cancer the leading cause of death related to diseases in this age group. The full study can be found hereto.
In Brazil, during the Big Data Oncology Forum (2019), the increase in cancer cases in the population between 20 and 49 years old, from 1997 to 2016, attracted the attention of specialists. During this period, the annual incidence of thyroid cancer increased by 8.8%, prostate cancer 5.2%, and colon and rectal cancer 3.4%. The data are part of the study prepared by the Oncology Observatory, whose theme was Cancer before 50: how data can help with prevention policies. According to the study, there was also an increase in mortality from some types of the disease. The highest percentage was cancer in the body of the uterus, which rose 4.2% per year; followed by colon and rectum with 3.2%, breast 2.5%, oral cavity 1.2%, and cervix 1% . (Information from Agência Brasil)
Dr. Eduardo Romero also points out that “in Brazil, in addition to the increase in cases, there is also an increase in mortality, due to the difficulties we face in our country regarding access to health, both for prevention, screening, early diagnosis and appropriate treatment”. The oncologist also reinforces that “cancer does not choose age, sex, race, religion or place, it is present in our lives more and more. Therefore, do your routine exams, always go to your doctor and discuss with him if there are tests at your age that can be performed for screening and early diagnosis of cancer. Always be aware of symptoms that may be suggestive of neoplasia, but don't wait for symptoms to see a doctor, go to the doctor routinely”.
Below are some examples of tests and vaccines selected by Dr. Eduardo Romero that may contribute to the prevention and early treatment of some types of cancer:
- Breast cancer: mammography exam (starting at age 40 or earlier if there were breast lumps or family history of neoplasia) and breast US (all ages)
- Cervical cancer: pap smear, oncotic cytology, or preventive examination (beginning at age 25)
- Bowel cancer: colonoscopy (beginning at age 45 or earlier if symptoms or family history)
- HPV vaccine: boys from 11 to 14 years old and girls from 9 to 14 years old (available at SUS). The vaccine can prevent cancer of the cervix, vulva, vagina, penis, anus, and head and neck (oropharynx)
The content of this text is informational and does not replace the medical report. If you experience any of the symptoms described above, a doctor should be consulted.
Text by Letícia Barbosa
What is it?
Colorectal cancer, also known as colon, rectum, or bowel cancer, is a tumor that develops in the large intestine. The disease, which develops from polyps (benign lesions) that grow on the wall of the large intestine, is treatable and, in most cases, curable, if detected early.
According to data from the National Cancer Institute (INCA), colorectal cancer is the third most common among men, after prostate and lung cancer. Among women, it is the second most common, second only to breast cancer.
Dr. Rodrigo Melão Martinho, from Cancer Institute Brazil, highlights that “the onset of CRC may be influenced by sporadic factors, which represent 70% to 80% of cases, and genetics”. According to data from the World Health Organization (WHO), 70% of cases could be prevented by changing habits and accessing colonoscopy, which allows, in addition to early diagnosis, the resection of polyps (precursor lesions).
Among the lifestyle-related risk factors highlighted by the doctor are: Obesity, sedentary lifestyle, excessive alcohol consumption, smoking, diet rich in red meat and processed foods. There are also factors that we cannot control, such as: age, family history, inflammatory bowel disease, and ethnicity. For this reason, Dr. Rodrigo warns “practice physical activity, eat a healthy and balanced diet, control excess weight and do not use drugs”.
Signs and symptoms
Unfortunately, in most cases, colorectal cancer has no symptoms, only 40% of colorectal cancers are diagnosed at an early stage.
However, some symptoms that may occur are:
• Diarrhoea or constipation.
• Feeling that the intestine is not completely emptied.
• Presence of blood in the stool.
• Cramping abdominal pain, a feeling of abdominal bloating.
• Tiredness and fatigue.
• Weight loss for no specific reason.
It is necessary to be aware, as these symptoms may also be associated with other diseases. However, if you have any of these symptoms, a doctor should be consulted for an accurate diagnosis and initiation of treatment if necessary.
(Source: Oncoguia)
Diagnosis and treatment
As colorectal cancer can be confused with other diseases and has a low diagnosis rate in its early stages, it is essential not to ignore the signs and symptoms. This is because investigating immediately and having an early diagnosis is essential for a more effective treatment.
Therefore, when experiencing the symptoms and seeking a specialist, the specialist can investigate the case and arrive at a diagnosis based on imaging tests, such as colonoscopy and rectosigmoidoscopy, and through a stool examination, which will search for the presence of hidden blood in the stool.
Surgery for colorectal cancer
Oncological surgery plays a fundamental role in the fight against cancer, since up to 90% of patients with oncological diseases will require some type of surgical procedure, either for treatment or diagnosis.
According to Dr. Diego Greatti Vaz da Silva, member of the Scientific Committee of the Brazilian Society of Regional Oncological Surgery of São Paulo (SBCO-SP), surgery on colorectal cancer patients is also necessary. “Treatments with curative intent against this disease include surgery to remove the affected intestinal segment. This surgical procedure is one of the most widespread among surgeons who treat cancer. Initially carried out in 1900, it underwent several technical and technological advances over the last few decades, becoming very safe and with low complication rates,” she explains.
Nowadays, minimally invasive surgery (videolaparoscopy and robotics) for the treatment of colorectal cancer is safe and preferred for most cases. Dr. Diego clarifies that with it, the abdominal incision and surgical trauma are smaller, expediting surgical recovery. In robotic surgery, the procedure is performed by a qualified surgeon controlling the clamps of a robot, which execute the movements delicately and with greater precision on the patient. When available, this route facilitates surgery mainly on tumors located in the lower rectum, closer to the anus.
What's new in colorectal cancer research
Dr. Caio Rocha Lima, oncologist, researcher, and clinical oncology professor at Wake Forest University - North Carolina, highlights two promising initiatives in cancer research colorectal: immunotherapy and DNA technology.
In immunotherapy, Dr. Caio explains that the solution is focused on colon cancer with microsatellite instability. This type affects around 5% of patients with metastatic colon cancer and around 15% of patients with stage 2 and 3 cancer. This type of cancer may be related to genetic (Lynch syndrome) or somatic (non-genetic) predisposition. Immunotherapy treatment consists of boosting the immune system so that it can fight diseases such as cancer.
Another important research area cited by Dr. Caio is dedicated to detecting the recurrence of circulating cancer cells (ctDNA) with DNA technology. This technology is superior in detecting recurrence compared to monitoring recurrence with radiology (CT scan, MRI, or PET scan) or with tumor markers, such as CEA.
The content of this text is informational and does not replace the medical report. If you experience any of the symptoms described above, a doctor should be consulted.
Throughout history, whether as scientists, health professionals, caregivers, or patients, women have played a vital role in the fight against cancer. Although gender inequalities remain, women are able to occupy more leadership and activism positions in the areas of health and science, which has the power to positively impact the attention, care, and access to information of women who are cancer patients or who accompany family members, partners, or friends who are undergoing cancer treatment.
Considering how female participation in this area can help inspire other women to tell their stories and raise the flag of scientific research, we highlight below the inspiring initiatives of some of the many women who work for a common goal: the fight against cancer and the well-being of cancer patients.
USP scientists develop immunotherapy against HPV
Researchers Luana Moraes, Bruna Porchia and Mariana Diniz from the Institute of Biomedical Sciences (ICB) at USP seek to complete the development of an immunotherapy, called Terah-7. Treatment is aimed at tumors caused by the HPV virus, such as cervical cancer. Terah-7 is able to direct and activate the immune system itself, inducing a specific response to fight the tumor, without harming patients' healthy cells. Source: USP Journal.
Queer activist Ericka Hart has been promoting debates about breast cancer
After being diagnosed at 28 with breast cancer, the same disease that brought her mother, Ericka Hart was shocked and decided to take action. In 2016, she attended the music festival and exposed her mastectomy scars on stage to draw attention to the disease. His act had repercussions on the media and social networks. Since then, Ericka, who is also a sex educator, has used her fame to raise awareness, especially among black Queer and Trans people, about breast cancer and discuss medicine, gender, sexuality, and racism.
A member of the Cura Project Institute, she has overcome two cancers and uses her work to raise awareness and educate about the disease
Paula Dutra has been part of the Cura Project Institute team since 2017, is an advertiser and design specialist, and is responsible for taking care of our social networks! Paula has had breast and ovarian cancer and for this reason she participated in clinical research and is a great supporter of encouraging research to combat cancer. Since her first diagnosis in 2011, Paula decided to share her story and the step by step of her treatment with other women. Thus, she created a support network and experience sharing on the blog Mão na Mama @maonamama, where she also gives tips on health and self-care.
Dr. Angélica Nogueira is an oncologist and researcher and holds leadership positions in several institutions that are committed to a didactic and preventive approach to the fight against cancer.
Dr. Angélica is an example of determination and leadership. The doctor was the creator of the Brazilian Gynecological Tumors Group (EVA Group), which seeks to promote awareness and research in gynecological cancer. In addition, the institution defends the rights of cancer patients and supports them during treatment for the disease. Currently, in addition to chairing the EVA Group, Dr. Angélica is also director of the Brazilian Society of Clinical Oncology (SBOC), Chair Gynecology of the Latin American Cooperative Oncology Group (LACOG) and research professor at the Minas Gerais School of Medical Sciences and the Federal University of Minas Gerais.
#JuntasSomosMaisFortes
The Brazilian Cancer Institute (ICB) signed a new partnership this month with the Cura Project Institute and is now part of our team of monthly donors. The Brazilian Cancer Institute is based on the pillars of care, teaching and research with quality, capillarity and social responsibility. Since 2012, the Institute has been fighting to democratize the access of the population in the interior of Brazil to quality cancer treatments.
Former partner in publicizing the actions of the Cura Project Institute, the ICB works to create and manage clinical, surgical and radiotherapy structures for cancer treatments in hospitals, private clinics, and in partnerships with the Unified Health System (SUS), in several cities in Brazil.
In addition to working with some common objectives, the executive director of the Brazilian Cancer Institute, Dr. José Márcio, affirms that the ICB's collaboration with Cura grew out of admiration for the project. “What enchants us most about Cura is its DNA. The institution thinks big and is not afraid to face difficulties and challenges. Since its founding, it was born with the intention of mobilizing society and making the population aware of clinical research and raising funds for this purpose. That in itself is fantastic and is very much in line with our spirit of innovation and resilience.”
The director also reveals that his first impression of the Cura Project was very positive. “A few years ago when we met the embryo of the Cura Project at an event of LACOG, during a presentation by its president Fernanda Schwyter -with a lot of twinkling in our eyes-, we were sure that it was a project that we should support, both because it was in line with the mission, vision and values of our institution, and also because of the quality and credibility of the people involved”, recalls Dr. José Márcio.
Now, we celebrate a new step in the partnership between the Cancer Institute Brazil and the Cura Project, the ICB becomes one of monthly donors from the Cura Project. Regarding the initiative, the president of the Cura Project Institute, Fernanda Schwyter, comments that “the partnership with the ICB will allow us to increase our awareness campaigns about the benefits of research in the fight against cancer, as well as in its funding. This partnership will also help us create a stronger and more engaged team so that we can further disseminate the philanthropic message of Cura and the importance of scientific research in the region”
The Cura Project Institute is the only organization in Latin America dedicated to planning and executing awareness-raising actions and raising funds to support various researches aimed at combating cancer - a disease that claims many victims around the world. Therefore, the collaboration of individuals and legal entities with the culture of philanthropy is essential so that scientists can continue their work and, through research, find treatments and cures for the most diverse cancers.
Dr. José Márcio also reinforces the importance of the act of donating and argues that “serious and non-profit institutions, with enormous social responsibility, such as the Cura Project Institute, must always be supported. Even more so when these institutions envision the improvement of our society as a whole”. The director of the ICB also invites “Everyone come with us! We are sure that initiatives such as the Cura Project Institute will contribute to an environment of engagement of individuals, companies and public managers in this very important struggle”.
Text by Letícia Barbosa
Follow CURA on social media
© 2023 Cura Project Institute. All rights reserved.
.jpg)
_20250718_163507_0000.png)
